Sargent Investment Group LLC Has $3.29 Million Stake in Danaher Corporation (NYSE:DHR)

Sargent Investment Group LLC boosted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 14.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,038 shares of the conglomerate's stock after purchasing an additional 2,080 shares during the period. Sargent Investment Group LLC's holdings in Danaher were worth $3,288,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Lindbrook Capital LLC boosted its position in shares of Danaher by 6.8% during the 1st quarter. Lindbrook Capital LLC now owns 5,156 shares of the conglomerate's stock worth $1,057,000 after purchasing an additional 330 shares in the last quarter. Milestones Administradora de Recursos Ltda. boosted its position in shares of Danaher by 167.1% during the 1st quarter. Milestones Administradora de Recursos Ltda. now owns 9,350 shares of the conglomerate's stock worth $1,917,000 after purchasing an additional 5,850 shares in the last quarter. OneAscent Financial Services LLC boosted its position in shares of Danaher by 205.9% during the 1st quarter. OneAscent Financial Services LLC now owns 3,350 shares of the conglomerate's stock worth $686,000 after purchasing an additional 2,255 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of Danaher by 53.8% during the 1st quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate's stock worth $42,000 after purchasing an additional 71 shares in the last quarter. Finally, OneAscent Family Office LLC boosted its position in shares of Danaher by 114.9% during the 1st quarter. OneAscent Family Office LLC now owns 2,454 shares of the conglomerate's stock worth $502,000 after purchasing an additional 1,312 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DHR shares. Guggenheim reaffirmed a "buy" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday. TD Cowen increased their price objective on shares of Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research note on Wednesday, April 23rd. UBS Group decreased their price objective on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $248.48.

Insider Activity

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

Danaher Stock Performance

NYSE DHR opened at $189.98 on Friday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The company has a market capitalization of $135.96 billion, a P/E ratio of 36.89, a P/E/G ratio of 2.67 and a beta of 0.77. The company has a fifty day moving average of $196.13 and a 200-day moving average of $205.03.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. As a group, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.67%. Danaher's dividend payout ratio is currently 24.85%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.